Patient

Treatment scedule

# of cycles of nab-paclitaxel

Response

TTP (mos)

Survival from nab-paclitaxel start (mos)

OS (mos)

Further therapies

1

100 mg/m² weekly 3/4

7

Progression^*

1.5

7.2

20.5

None

2

125 mg/m² weekly 3/4

9

Partial response

8.8

20.7

32.5

MEK + BRAF inhibitor combination^†, irinotecan

3

125 mg/m² q2 weeks

4 alone, then 4 with gemcitabine

Stable

3.7

9.8

35.9

None

4

100 mg/m² weekly 3/4

4

Stable

2.8

3.3

11.7

None

5

100 mg/m² weekly 3/4

7

Stable

3.8

6.6

41.4

None